Synthesis and PC3 androgen-independent prostate cells antiproliferative effect of fegaronine derivatives

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 22, Issue 5, 2007, Pages 647-654

  Vanquelef, Enguerran ^a   Hélesbeux, Jean Jacques ^a   Duval, Olivier ^a   Debiton, Eric ^b,d   Barthomeuf, Chantal ^b,d   Jarry, Christian ^c   Forfar, Isabelle ^c   Richomme, Pascal ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSERM   (France)

Author keywords

Benzo c phenanthridine; Fagaronine; Log D; PC3 androgen independent cell line

Indexed keywords

12 ETHOXY 3,8,9 TRIMETHOXY 5 METHYL 2 OCTANOYLOXY 5,6 DIHYDROBENZO[C]PHENANTHRIDINE; 12 ETHOXY 3,8,9 TRIMETHOXY 5 METHYL 2 OCTANOYLOXYBENZO[C]PHENANTHRIDINE IODINE; 2 ISOPROPOXY 3,8,9 TRIMETHOXY 5 METHYL 4B,5,6,12 TETRAHYDROBENZO[C]PHENANTHRIDINE; 2 ISOPROPOXY 3,8,9 TRIMETHOXY 5 METHYLBENZO[C]PHENANTHRIDINIUM IODIDE; 3 (4 HYDROXY 3 METHOXYPHENYL) 6,7 DIMETHOXY 4 VINYL 1,2,3,4 TETRAHYDROISOQUINOLIN 4 OL; 3 (4 ISOPROPOXY 3 METHOXYPHENYL) 6,7 DIMETHOXY 4 VINYL 1,2,3,4 TETRAHYDROISOQUINOLIN 4 OL; 3 (4 MESYLOXY 3 METHOXYPHENYL) 6,7 DIMETHOXY 4 VINYL 1,2,3,4 TETRAHYDROISOQUINOLIN 4 OL; ANDROGEN; ANTINEOPLASTIC AGENT; BENZO[C]PHENANTHRIDINE DERIVATIVE; FAGARONINE; FAGARONINE CHLORIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; PH; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 35348998504     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360701485901     Document Type: Article

References (19)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Smigal, C. and Thun, MJ (2006) CA Cancer J Clin, 56, pp. 106-130.
2. Gronberg, H. (2003) Lancet, 361, pp. 859-864.
3. Suffness, M. and Cordell, GA (1985) "The Alkaloids", 25, pp. 178-187. Academic, New York
4. Simanek, V. (1986) In The Alkaloids, 26, pp. 229-230. Academic Press, Orlando, FL
5. Simeon, S., Rios, JL and Villar, A. (1989) Pharmazie, 44, pp. 593-597.
6. MacKay, SP, Meth-Cohn, O. and Waigh, RD (1997) Adv. Heterocyclic Chem., 67, pp. 345-388.
7. Messmer, WM, Tin-Wa, M., Fong, HHS, Bevelle, C., Farnsworth, NR, Abraham, DJ and Trojanek, J. (1972) J Pharm Sci, 61, pp. 1858-1859.
8. Ishikawa, T. and Ishii, H. (1999) Heterocycles, 50, pp. 627-639.
9. Ianoul, A., Fleury, F., Duval, O., Waigh, R., Jardillier, JC, Alix, AJP and Nabiev, I. (1999) J Phys Chem, 103, pp. 2008-2013.
10. Wang, LK, Johnson, RK and Hecht, SM (1993) Chem Res Toxicol, 6, pp. 813-818.
11. Mackay, SP, Comoe, L., Desoize, Duval, O., Jardillier, JC and Waigh, RD (1998) Anti-Cancer Drug Design, 13:7, pp. 797-813.
12. Fleury, F., Sukhanova, A., Ianoul, A., Devy, J., Kudelina, I., Duval, O., Alix, AJP, Jardillier, JC and Nabiev, I. (2000) J Biol Chem, 275, pp. 3501-3509.
13. Lynch, MA, Duval, O., Sukhanova, A., Devy, J., MacKay, SP, Waigh, RD and Nabiev, I. (2001) Bioorgan & Med Chem Lett, 11, pp. 2643-2646.
14. Pehourcq, F., Thomas, J. and Jarry, C. (2000) J Liq Chromatogr Relat Technol, 23, pp. 443-453.
15. Hiroto, I., Takayuki, T., Hiroshi, I., Hidetaka, U., Yoichiro, Y., Mizuho, T., Tomoko, I., Tadashi, M., Takeshi, Y., Minoru, N. and Kimitoshi, K. (2003) Cancer Treat Rev, 29, pp. 541-549.
16. O'Brien, J., Wilson, I., Orton, T. and Pognan, F. (2000) Eur J Biochem, 267, pp. 5421-5426.
17. Rago, R., Mitchen, J. and Wilding, G. (1990) Anal Biochem, 191, pp. 31-34.
18. Kerry, MA, Duval, O., Waigh, RD and MacKay, SP (1998) J Pharm Pharmacol, 50, pp. 1307-1315.
19. Kock, I., Heber, D., Weide, M., Wolschendorf, U. and Clement, B. (2005) J Med Chem, 48, pp. 2772-2777.